Comparison · NCT01732913-sae
Idelalisib + Rituximab vs Placebo + Rituximab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Idelalisib + Rituximab vs Placebo + Rituximab: serious adverse events. Trial comparisons, record NCT01732913-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01732913-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.52 | 0.451 | 0.589 | wilson | |
| Risk in group 2 | 0.116 | 0.0659 | 0.196 | wilson | |
| Risk difference, group 1 minus group 2 | 0.404 | 0.299 | 0.489 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 4.49 | 2.54 | 7.96 | log | |
| Odds ratio, group 1 over group 2 | 8.28 | 4.16 | 16.5 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Idelalisib + Rituximab than on Placebo + Rituximab | 2.47 | 2.04 | 3.35 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Idelalisib + Rituximab | Idelalisib 150 mg tablet orally twice daily + rituximab 375 mg/m\^2 intravenously starting on Day 1 for a total of 8 infusions | 103 | 198 | EG000 |
| Group 2 | Placebo + Rituximab | Placebo tablet orally twice daily + rituximab 375 mg/m\^2 intravenously starting on Day 1 for a total of 8 infusions | 11 | 95 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 27 months plus 30 days
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
- NCT number
- NCT01732913
- Phases
- PHASE3
- Conditions
- Indolent Non-Hodgkin's Lymphomas
- Interventions
- Placebo, Rituximab, Idelalisib
- Lead sponsor
- Gilead Sciences
- Results first posted
- 2017-05-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01732913?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01732913-sae